Phase 2 N=74 Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen
Acute Myeloblastic Leukemia
Primary: Cumulative Incidence of Non Relapse Mortality (NRM) — 21 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=17 Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings
Cystic Fibrosis
Primary: Sputum Wet and Dry Weight — 6.4; 4.8; 0.20; 0.12 grams — p=.02
Phase 2 N=28 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Tourette Syndrome
Primary: Total Tic Severity Score (Part 2 Only) Crossover Analysis Over 6 Periods — 24.32; 25.41; 22.99 Total Tic Severity Score — p=0.0087
Phase 4 N=27 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virologic Response at 24 Weeks Following Treatment Completion — 55.6 Percentage of participants
Phase 1 N=82 TAK-114 Single- and Multiple-Dose Phase 1 Study
Clinical Pharmacology
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) — 0; 0; 1; 1 participants
Phase 3 N=86 Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
Breast Cancer · Fatigue · Sleep Disorders
Primary: Change in Cognitive Function Over 1 Year in Premenopausal Breast Cancer Patients Who Receive Adjuvant Tamoxifen (T) Alone Against Those Receive Adjuvant Tamoxifen…
N/A N=53 Dynasplint Therapy for Trismus in Head and Neck Cancer
Trismus
Primary: Number of Participants Demonstrating Improved MIO Using Either the Dynapslint System or Tongue Depressors — 12; 12; 7; 7 participants
Phase 1 N=19 Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C
Advanced Gastrointestinal Malignancies
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Phase 2 N=59 Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Adrenocortical Adenoma · Endometrial Stromal Sarcomas
Primary: Incidence of Adrenal Cortical Adenomas — 3 Particpants
Phase 3 N=329 A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Phase A, FAS Population) — -0.49; -0.10 Percent — p=<0.001
Phase 2 N=18 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
Gastrointestinal Cancer Metastatic · Renal Cell Cancer Metastatic · Non Small Cell Lung Cancer Metastatic
Primary: Progression Free Survival
Phase 4 N=79 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Number of Participants With Positive Antibody Responses to at Least One of the 23 Pneumococcal Vaccine Serotypes 4 Weeks Post-vaccination — 32; 40 Participants
Phase 2 N=10 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Adult Alveolar Soft Part Sarcoma · Adult Angiosarcoma · Adult Desmoplastic Small Round Cell Tumor
Primary: Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level…
Phase 4 N=59 An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Percentage of Participants Achieving Hepatitis C Virus Deoxyribonucleic Acid <10,000 Copies/Milliliter at Week 72 — 65.4 Percentage of participants
Phase 3 N=75 A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.
Anemia
Primary: Mean Change in Hb Concentration Between Baseline and the Efficacy Evaluation Period — 1.99 g/dL